Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol

Next Previous
Trial Profile

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Haematological malignancies; Tumour lysis syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms FLORENCE
  • Sponsors Menarini

Most Recent Events

  • 27 Jul 2015 Results published in the Annals of Oncology.
  • 30 Jun 2015 According to a Teijin Pharma media release, Menarini has received approval for febuxostat [Adenuric] in Europe for an expanded indication of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumor lysis syndrome. The approval is based on positive results from this trial.
  • 02 Jun 2015 Results assessing compliance of sites presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top